After hours:
Chart Events
Performance Outlook
| Previous Close | 6.70 |
| Open | 6.55 |
| Bid | 6.41 x 1300 |
| Ask | 6.42 x 800 |
| Day's Range | 6.33 - 6.70 |
| 52 Week Range | 4.21 - 22.22 |
| Volume | |
| Avg. Volume | 818,693 |
| Market Cap | 423.681M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CDXS
Related Research
- Codexis, Inc.Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.RatingFair ValueEconomic Moat2 days agoMorningstar
- Simply Wall St.
Codexis (NASDAQ:CDXS) shareholders have endured a 68% loss from investing in the stock a year ago
Over the last month the Codexis, Inc. ( NASDAQ:CDXS ) has been much stronger than before, rebounding by 41%. But that's...
- GlobeNewswire
Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company’s financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. “I am ex
- GlobeNewswire
Codexis Announces Appointment of H. Stewart Parker to Board of Directors
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. “Stewart’s deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background,
